Acro Biotech Highlights Expanded Toxicology and Rapid Diagnostic Portfolio

Acro Biotech is presenting its extensive product range at MEDICA 2025 that includes approved drugs of abuse tests, women’s health related rapid tests, cardiac markers, tumor markers, among others.

Exhibiting at booth C40-5 in Hall 3, the company invites attendees to explore a portfolio spanning drugs of abuse (DOA) testing, fluorescence immunoassay (FIA) panels, and urine analysis. On display are new DOA rapid tests for Scopolamine (SCOP), Citalopram (CIT), and Fentanyl (FYL), reflecting demand for broader toxicology coverage in hospital and occupational health workflows.

Image: Acro Biotech invites attendees to explore a portfolio spanning DOA testing, FIA rapid test kits, and urine analysis (Photo courtesy of Acro Biotech)

For laboratory medicine applications, the company’s booth features FIA tests covering cardiac and endocrine markers, including Troponin I/Myoglobin/CK‑MB (creatine kinase‑MB), Prolactin, and Vitamin D. Instrumentation on display includes the Apoti Plus Fluorescence Immunoassay Analyzer (1 Channel) for benchtop use, the AcrMove Up Handheld Fluorescence Immunoassay Analyzer for mobile testing, and the Optilyte Plus Urine Analyzer to support routine urinalysis.

The lineup also includes the Urine Cup for Multi‑Drug Testing aimed at streamlined specimen collection and rapid screening. At the company's booth, specialists will provide live demonstrations and discuss implementation to align with laboratory and near‑patient workflows across emergency care, toxicology, and chronic disease monitoring.

Related Links:
Acro Biotech